



Industry Product Theatre: IPT02

Industry session financially supported by Teva Pharmaceuticals during the 38th ECNP Congress

Breaking the Silence: A New Chapter in Tardive Dyskinesia Management after Decades

Sunday 12 October 2025 15:20 - 15:50

Room G104



Prof. Sofia Pappa,
Professor of Practice in Psychiatry,
Imperial College London.

Tardive dyskinesia (TD), despite being disabling and stigmatizing, is under-recognized, and may be misdiagnosed or ignored. Moreover, it can be challenging to manage the underlying psychiatric disorder alongside TD symptoms¹.

Join us at this Product Theatre to navigate the complexities of TD management and discuss evidence-based practices to improve care.



1. Caroff S. Neuropsychiatr Dis Treat. 2019;15:785–794.

This material is intended for HCPs only

NPS-NL-NP-00225
Date of Preparation: July 2025

Teva Pharmaceuticals Europe BV, Busweg 1,
2031 DA Haarlem, Netherlands. KvK 003973190.

teva